Phase I Combination Ixabepilone + Cisplatin
Completed · Phase 1
Conditions studied: Non Small Cell Lung Cancer
In brief
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the effects (good or bad) on your cancer will also be studied
Key facts
- Study ID
- NCT00832117
- Run by
- R-Pharm
- People needed
- 30
- Starts
- 2009-05-01
- Expected to finish
- 2011-01-01
- Last updated by the study team
- 2020-10-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Men and women age ≥ 18
- Exclusion:
- More than 2 prior chemotherapy containing regimens for metastatic disease
- No prior exposure to cisplatin or ixabepilone
- Expansion Phase Subjects: Advanced Non-small cell lung cancer
- Inclusion Criteria:
- Men and women age ≥ 18
- Exclusion:
- No prior chemotherapy-containing regimen for metastatic disease
- No prior exposure to cisplatin or ixabepilone
Where it is running
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- The Cancer Institute Of New Jersey — New Brunswick, New Jersey, United States
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States
- Local Institution — Lucca, Italy
- Local Institution — Meldola (Fc), Italy
- Local Institution — Rimini, Italy
- Local Institution — Viterbo, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.